| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 60 |
| 1 | PEMBROLIZUMAB | 54 |
| 2 | IPILIMUMAB | 24 |
| 3 | ASPIRIN | 21 |
| 4 | ASPIRIN 325 MG | 21 |
| 5 | ASPIRIN 81 MG | 21 |
| 6 | CARBOPLATIN | 21 |
| 7 | METOPROLOL TARTRATE | 20 |
| 8 | METOPROLOL | 19 |
| 9 | ACETAMINOPHEN | 14 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ALDESLEUKIN | 8 | 0.0063 |
| 1 | DOSTARLIMAB | 7 | 0.0028 |
| 2 | ESTAZOLAM | 5 | 0.0025 |
| 3 | AVELUMAB | 7 | 0.0017 |
| 4 | PROCHLORPERAZINE EDISYLATE | 2 | 0.0017 |
| 5 | BELZUTIFAN | 2 | 0.0011 |
| 6 | CEMIPLIMAB-RWLC | 2 | 0.0010 |
| 7 | TRIMIPRAMINE | 1 | 0.0009 |
| 8 | MINERAL OIL | 1 | 0.0007 |
| 9 | POTASSIUM IODIDE | 1 | 0.0007 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 129 |
| 1 | Nonsteroidal Anti-inflammatory Drug [EPC] | 33 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 25 |
| 3 | Corticosteroid [EPC] | 25 |
| 4 | Platinum-based Drug [EPC] | 25 |
| 5 | Platelet Aggregation Inhibitor [EPC] | 21 |
| 6 | Atypical Antipsychotic [EPC] | 18 |
| 7 | Loop Diuretic [EPC] | 14 |
| 8 | Benzodiazepine [EPC] | 13 |
| 9 | Kinase Inhibitor [EPC] | 13 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Growth Factor [EPC] | 8 | 0.0063 |
| 1 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 129 | 0.0013 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 25 | 0.0005 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 10 | 0.0005 |
| 5 | Antifibrinolytic Agent [EPC] | 2 | 0.0002 |
| 6 | Provitamin D2 Compound [EPC] | 5 | 0.0002 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 8 | Sulfonylurea [EPC] | 13 | 0.0001 |
| 9 | Thyroid Hormone Synthesis Inhibitor [EPC] | 1 | 0.0001 |